冠心病患者肺炎衣原体感染与血脂水平相关性研究

目的 探讨血脂表达水平与冠心病患者肺炎衣原体IgG及炎症表达的相关性,为冠心病的预防和治疗提供参考.方法 选择在该院心内科住院的冠心病患者50例作为冠心病组,同期在该院心内科门诊就诊的非冠心病患者28例作为对照组,比较两组之间的血脂表达、肺炎衣原体（Cpn）IgG（免疫球蛋白G）阳性率和炎症表达.结果 冠心病组的TC（总胆固醇）、TG（甘油三酯）、LDL-C（低密度脂蛋白胆固醇）,其水平分别为（4.75±1.33）、（1.67±0.82）、（2.88±0.86）mmol·L-1,明显高于对照组的（3.96±1.07）、（1.05±0.42）、（2.12±0.47）mmol±L-1（P＜0.05）;冠心病组血清中Cpn（肺炎衣原体） IgG（免疫球蛋白G）抗体阳性率为76.7%,明显高于对照组的21.2%（P＜0.05）;冠心病组CRP（C-反应蛋白）、IL-6（白介素-6）、TNF-α（肿瘤坏死因子-α）,其水平分别为（5.8±1.6）、（15.8±7.62）、（16.1±2.2）mg·L-1,明显高于对照组的（3.85±0.87）、（6.5±1.53）、（5.5±1.6）mg·L-1（P＜0.05）;冠心病发展的不同阶段SAP（稳定型心绞痛）、UAP（不稳定型心绞痛）、AMI（急性心肌梗死）,LCI（血脂综合指数）水平逐渐升高,血清中CRP（C-反应蛋白）、sCD40L（人可溶性CD40配体）、MMP-9（金属蛋白酶-9）的水平也逐渐升高.结论 血脂表达水平与冠心病患者炎症表达存在明显的相关性.脂质代谢紊乱、CRP（C-反应蛋白）升高与Cpn（肺炎衣原体）感染发生协同作用,促使炎症高表达,诱发及加重动脉粥样硬化,从而引起冠心病发生发展.     

血锂浓度正常时锂盐中毒的病例报告(英文)

患者是一名18岁的女性,因首次躁狂发作而入院。给予常规剂量的碳酸锂治疗,两周后她的症状缓解;随即出院,在家服药剂量为250 mg,每天两次。出院五天后,她由于食欲差和意识模糊被送入一家综合医院急诊室。由于综合医院医师无法诊断该问题,患者被转诊送入我院。虽然入院时血锂浓度为0.57 mmol/L(即,治疗量的下限),但是她已经表现出锂盐中毒的症状,包括无尿,四肢震颤、吐词不清、肌张力升高、和腱反射亢进。给予甘露醇静滴,她的急性症状很快得到缓解。此病例说明,无论血锂浓度的高低,对使用锂盐的患者必须监测锂盐中毒的临床症状;同时必须告知患者、家属、和普通医师锂盐中毒的症状和处理。     

超声体检发现血脂正常者患脂肪肝原因分析

目的 对体检发现血脂正常但确诊为脂肪肝患者的患病原因做出统计分析.方法 对2012年01月至2014年1月来我门诊体检发现的150例血脂正常的脂肪肝患者和150例血脂正常的非脂肪肝患者的临床资料进行回顾性分析,对临床表现为血脂正常但患脂肪肝的原因进行回归统计分析.结果 血脂正常的脂肪肝患者和血脂正常的非脂肪肝患者在肥胖情况、高血糖情况、嗜酒情况三方面差异显著,具有统计学意义（P＜0.05）.在肝炎情况、服用肝损伤药物病史情况存在差异,但是差异减小,不具有统计学意义（P＞0.05）.结论 即使血脂正常也具有患脂肪肝的概率,血脂正常者患脂肪肝的主要原因为过度肥胖、高血糖以及嗜酒.     

二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床研究

目的 探讨二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床疗效。方法 选择2010年1月—2014年1月安阳市第三人民医院收治的多囊卵巢综合征患者100例,随机分为治疗组（50例）和对照组（50例）。对照组患者自月经第5天开始口服炔雌醇环丙孕酮片,每晚1片,连服21 d,待撤退性出血第5天开始下一疗程治疗。治疗组在对照组治疗基础上,进餐前30 min口服盐酸二甲双胍片,1片/次,3次/d。两组均连续治疗3个疗程。治疗后,对两组的临床疗效进行评价,同时对两组患者的性激素水平、胰岛素抵抗指数（HOMA-IR）、胰岛素分泌指数（HOMA-β）、排卵率、妊娠率进行比较。结果 治疗组和对照组总有效率分别为96.0%、78.0%,两组比较差异有统计学意义（P<0.05）。治疗后,两组患者的促黄体生成素（LH）、促卵泡生成素（FSH）、睾酮（T）水平均较治疗前显著降低,雌激素（E₂）较治疗前显著升高,同组治疗前后差异有统计学意义（P<0.05）;且治疗后治疗组患者的性激素水平改善程度明显优于对照组,两组比较差异有统计学意义（P<0.05）。治疗后,两组患者HOMA-IR、HOMA-β均较治疗前显著降低,治疗前后比较差异有统计学意义（P<0.05）,且治疗后治疗组这两个指数均低于对照组,两组比较差异有统计学意义（P<0.05）。治疗组排卵率和妊娠率均显著高于对照组,两组比较差异有统计学意义（P<0.05）。结论 二甲双胍联合炔雌醇环丙孕酮片对多囊卵巢综合征有较好的临床疗效,可改善患者的性激素水平,提高患者的妊娠率,值得临床推广应用。     

Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta-analysis

Aims/IntroductionIn recent years, mesenchymal cellular therapies have received much attention in the treatment of diabetes. In this meta‐analysis, we aimed to evaluate the efficacy of mesenchymal stem cell therapy in type 2 diabetes mellitus patients.Materials and MethodsA comprehensive literature search was carried out using PubMed, Scopus, Web of Science and Central databases. A total of 1,721 articles were identified, from which nine full‐text clinical trials were qualified to enter the current meta‐analysis. The assessment groups included patients with type 2 diabetes, and levels of C‐peptide, glycosylated hemoglobin and insulin dose were analyzed before and after mesenchymal stem cell infusion. Data analysis was carried out in Stata version 11, and the Jadad Score Scale was applied for quality assessment.ResultsChanges in levels of C‐peptide after mesenchymal stem cell therapy were: standardized mean difference 0.20, 95% confidence interval −0.61 to 1.00, glycosylated hemoglobin levels were: standardized mean difference −1.45, 95% confidence interval −2.10 to −0.79 and insulin dose were: standardized mean difference −1.40, 95% confidence interval −2.88 to 0.09.ConclusionsThis meta‐analysis of prospective studies showed associations between mesenchymal stem cell therapy and control of glucose level in patients with type 2 diabetes.     

Six month assessment of low dose rituximab in the treatment of rheumatoid arthritis during coronavirus disease 2019 (COVID-19) pandemic

Aim of the workTo evaluate the 6-month treatment responses to low dose rituximab (LDR) compared to standard dose rituximab (SDR) in rheumatoid arthritis (RA) patients whose treatments were disrupted due to the pandemic with increased disease activity and to examine the effect of LDR treatment on serum immunoglobulin (Ig) levels.Patients and methodsRecords were retrospectively analysed for 80 patients on SDR not admitted to the hospital due to fear of infection during pandemic, with increased disease activity and were resumed on LDR (500 mg intravenous RTX-infusion twice with 15 days intervals, and repeated for the second time in all patients after 6 months). Disease activity score (DAS-28) values were obtained. The Ig levels of the patients before and after rituximab treatment were calculated.ResultsThe mean age of patients was 55.1 ± 13.1 years. They were 46 (57.5%) female and 34 (42.5%) male (F:M 1.4:1) with median disease duration of 13 (0.5–50) years. After the second dose of LDR, there was a significant decrease in the disease activity DAS28 (6.5 ± 1.01 to 3.2 ± 1.2, p < 0.0001) and acute phase reactants with a tendency to decrease in Ig levels. After LDR, 6 (7.5%) patients developed COVID-19 infection that did not require hospitalization. There was no difference between the Ig levels of patients with and without COVID-19 infection.ConclusionsLDR is an effective treatment option in the treatment of RA. In our study, none of our patients developed severe COVID-19 infection requiring hospitalization, and LDR may be preferred during the COVID-19 pandemic period.     

The association between metabolic syndrome and the anti-aging humoral factor klotho in middle-aged and older adults

Background and aimsThe goal of the present study was to determine the association between metabolic syndrome (MetS) and serum klotho levels (pg/ml) in middle-aged and older adults.Material and methodsThe National Health and Nutrition Examination Survey database from the cycles 2013–2014 and 2015–2016 were used to examine serum klotho levels in subjects with MetS and its components defined according to the 2009 Harmonizing Joint Scientific Statement. Sex-specific general linear models adjusted for potential confounders were assembled to compare mean log klotho levels between subjects with MetS and their healthy counterparts.ResultsOf 5069 participants aged 40–79 years, the prevalence of MetS was 44.8% in men and 45.1% in women. Overall, older adults, men, non-Hispanic whites, smokers, alcohol users, and subjects with decreased renal function were characteristics associated with lower klotho levels. Notably, serum klotho levels in women progressively decreased as the number of MetS components increased. Multivariate models demonstrated that women with MetS had significantly lower mean log klotho levels (6.65 vs. 6.70; P < .05) than those who did not. Likewise, abdominal obesity (6.5 vs. 6.68; P < .05) and elevated triglycerides levels (6.64 vs 6.68; P < .05) were the MetS components independently correlated with lower klotho levels.ConclusionsMetS in middle-aged and older adults was significantly and inversely associated with serum klotho levels. This association was particularly seen in women, and subjects with abdominal obesity or elevated triglycerides.     

Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort

Background and study aimTherapeutic drug monitoring (TDM) through measurement of infliximab (IFX) trough levels and antibodies to infliximab (ATI) is performed to guide IFX intensification strategies and improve its efficacy. We conducted this study to explore the relationship between clinical and endoscopic/radiological remission and IFX and ATI levels in patients with inflammatory bowel disease (IBD) treated with IFX and to evaluate the appropriateness of treatment decision post TDM.Patients and methodsThis was a cross-sectional study of a cohort of adult patients with IBD. Serum IFX trough concentrations and ATI were measured.ResultsA total of 129 patients [104] with ulcerative colitis (UC) and 25 with Crohn’s disease (CD)] were included in this study, of whom 61.2% were men. The mean disease duration was 6.7 years, and 72% of patients with UC had extensive colitis. The mean serum IFX trough level was 4.1 µg/mL; the IFX trough levels were subtherapeutic in 75 patients (58%), therapeutic in 37 patients (29%), and supratherapeutic in 17 patients (13%). Positivity to ATI was found in 16 patients (12.4%). Only 43 patients (33.3%) underwent an appropriate change in therapy after TDM, patients with penetrating CD disease had low IFX levels and higher C-reactive protein levels at 12 months before TDM.ConclusionsPatients with IBD with therapeutic IFX levels tend to have increased endoscopic/radiological remission rates. However, an appropriate change in management based on TDM was absent in the majority of patients, potentially reflecting the need to have a dashboard to support and guide clinicians in decision-making.